SUMMARY Three patients are reported who developed a melanoma while taking levodopa for Parkinson's disease. There were two cutaneous melanomas and one metastatic melanoma with occult primary. The literature on the association of Parkinson's disease, levodopa therapy and melanoma is reviewed. The capacity of levodopa to induce melanomas and its alleged adverse effect on the clinical course of the disease are questioned.
Levodopa has been used extensively in the treatment of Parkinson's disease since the early 1970s. Soon after its introduction Skibba et al reported a patient with Parkinson's disease who, whilst receiving levodopa, developed locally recurrent disease from a melanoma that had been excised 4 Levodopa and melanoma: three cases and review of literature as "typical primary melanomas". However, the clinical behaviour of this melanoma with multiple cutaneous lesions emerging simultaneously in the region of the primary site suggests that all these lesions were in fact cutaneous secondaries. Epidermotropism is not a feature peculiar to primary melanomas but may occur in cutaneous metastases as well. '2 A rather similar case was described by Bernstein et al.8 An elderly woman developed a level IV melanoma 10 years after she had been receiving levodopa and a decarboxylase inhibitor. The lesion, which was located on the scalp, was excised and a rotated skin flap was applied. The patient subsequently received local x ray therapy. Ten months later six tiny purple nodules arose within the area of the flap. The presence of epidermotropism led the authors to believe that these lesions represented local recurrences. One month later a 2 mm brown papule on the left foot was excised, exhibiting "moderately atypical melanocytes" in the epidermis only and a diagnosis of precancerous melanosis was made. Again 2 months later a flesh-coloured papule above the right eyebrow was excised. Primary melanoma was diagnosed. In this case the designation "distinct primary melanoma" for the foot lesion, showing no dermal invasion, is not borne out by the clinicopathological description. Also, the evidence furnished to classify the forehead lesion as a new primary is not firm. Differences between satellite and in-transit lesions and epidermotropic metastases on the one hand and primary melanomas on the other hand may be very subtle. ' 2 Slight acanthosis, absence of atypical melanocytes in the dermal vessels and tumour involvement of the entire dermis in a "nonzonal fashion" cannot be called characteristic features in favour of primary cutaneous melanoma. It is tempting to theorise that, where multiple local recurrences have emerged, a new lesion in the vicinity of the excision scar is not a new primary but also a sign of recurrent disease (satellite or in-transit metastasis).
Summarising the above it can safely be stated that the available literature data do not endorse the supposition that levodopa intake has an effect on malignant transformation of melanocytes. Likewise, there is no substantial evidence from the reported cases that levodopa therapy enhances melanoma growth. Thus far, two cases have been reported showing melanoma relapses after 4 and 2 months of levodopa therapy, respectively (nos. 1 and 4). These two cases prompt little concern and should be regarded as coincidental. In our third patient low back pain started 6 years after initiation of levodopa. The pain gradually intensified and after 3 years (!) metastatic melanoma was diagnosed. In this instance levodopa does not seem to have exerted a detrimental influence on the course of the melanoma and might even have been growth restraining.
Growth exacerbation of melanoma due to levodopa is often explained by the role levodopa plays in the biosynthetic pathway of melanin, in which it serves as a substrate for the rate-limiting enzyme tyrosinase. ' 
